{"prompt": "['Trial ID: LP0162-1339', 'Date: 29-Aug-2018', 'Version: 4.0', 'Page 71 of 129', 'subject using a 5-point scale (\\'no problems\\', \"slight problems\\', \"moderate problems\\', \\'severe', \"problems', and 'extreme problems'). The second section consists of a vertical visual analogue\", 'scale anchored at 0 (\\'the worst health you can imagine\\') and 100 (\"the best health you can', \"imagine'). The EQ-5D-5L will be completed electronically on the device supplied to the trial\", 'site according to the schedule of procedures (Section 4). The EQ-5D-5L is included in the', 'investigator trial file.', '10.3.2.10 Hospital Anxiety and Depression Scale', 'The HADS is a Likert-scale tool widely used to detect states of anxiety and depression in a', \"general hospital setting (33). The tool consists of 14 items that assess the subject's anxiety\", '(7 items) and depression (7 items) during the last week. Each question is scored from 0 to 3,', 'with high scores indicating a poor state. The HADS will be completed electronically on the', 'device supplied to the trial site according to the schedule of procedures (Section 4). The', 'HADS is included in the investigator trial file.', '10.4 Safety assessments', '10.4.1 Vital signs', 'Vital signs (resting blood pressure, pulse, and body temperature) must be assessed according', 'to the schedule of procedures (Section 4). Vital signs will be measured in supine position', \"following at least 5 minutes' rest.\", 'For the first 3 IMP dosing visits in both the initial treatment period (i.e., Weeks 0, 2, and 4)', 'and the continuation treatment period (i.e. Weeks 16, 18, and 20), subjects will be monitored', 'after IMP administration for immediate drug reactions for a minimum of 30 minutes with vital', 'signs taken at 30 minutes or until stable, whichever is later (Section 9.1.3.1).', 'If an abnormal vital sign at screening is considered by the investigator to be clinically', \"significant, it will be at the investigator's discretion if the subject should be randomised into\", 'the trial (respecting exclusion criterion no. 26).', 'In case of abnormal findings, the vital sign measurement can be repeated approximately', '15 minutes later with subjects resting in a supine position to verify the first measurement.', 'Should the repeated measurement result in a normal value, the measurement must be repeated', 'once more. If the third measurement verifies the second (normal) value, the first measurement', 'should be considered as false. If the third measurement confirms the first measurement', '(abnormal) the second measurement will be considered as false. Only the last value measured', 'and considered as correct will be recorded in the eCRF.', 'TMF-000005673 - Version 4.0']['Trial ID: LP0162-1339', 'Date: 29-Aug-2018', 'Version: 4.0', 'Page 72 of 129', 'Clinically significant abnormal vital signs at the first screening visit will be documented as', 'medical history in the eCRF. If an abnormal vital sign at any other visit than the first', 'screening visit is considered by the investigator to be clinically significant, it will be reported', 'as an AE in accordance with Section 11.2. Further, any clinically significant deterioration of a', 'pre-existing condition as well as any new clinically significant sign, symptom or illness', 'observed after screening will be reported as an AE in accordance with Section 11.2.', '10.4.2 Physical examination', 'A thorough physical examination of the subject including whole body inspection of the skin', 'and auscultation of heart, lungs and abdomen; palpation of the abdominal organs and basic', 'neurological status must be performed according to the schedule of procedures (Section 4).', 'If an unacceptable abnormal finding is identified during the physical examination at the', 'screening visit, the subject must not be randomised into the clinical trial (respecting exclusion', 'criterion no. 26).', 'Clinically significant abnormal physical examination findings at the first screening visit will', 'be documented as medical history in the eCRF. If an abnormal finding at any other visit than', 'the first screening visit is considered by the investigator to be clinically significant, it will be', 'reported as an AE in accordance with Section 11.2. Further, any clinically significant', 'deterioration of a pre-existing condition as well as any new clinically significant sign,', 'symptom, or illness observed after screening will be reported as an AE in accordance with', 'Section 11.2.', '10.4.3 Digital ECG', 'A single 12-lead resting digital ECG will be recorded after the subject has been supine for at', 'least 5 minutes at the visits indicated in the schedule of procedures (Section 4).', 'A pre-evaluation of the ECGs will be performed by the investigators to evaluate immediate', 'subject safety. At a minimum, date of ECG collection will be recorded in the source', 'documents.', 'The ECG data will be transferred to a central ECG service company for central evaluation. A', 'cardiologist at the ECG service company will analyse and interpret the ECG data. The ECG', 'service company will provide ECG evaluation reports to the trial sites.', 'The investigator must evaluate all abnormal ECG results (\\'clinically significant\\' or \"not', \"clinically significant') and sign and date. The investigator has the final decision on the clinical\", 'TMF-000005673 - Version 4.0']\n\n###\n\n", "completion": "END"}